Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease.

takeda-logoTakeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), which is the standard go-to drug for Alzheimer’s related dementia in up to 70 countries worldwide. Now they will collaborate with UK National Institute for Health Research (NIHR) endorsed teaching hospitals and the esteemed Institute for Neurology at UCL to concentrate on the effort to identify new gene targets for disorders of the central nervous system (CNS), of which there is a poorly understood cross-over.

Gene cross-over in Neurodegenerative disease is poorly understood in Parkinson's, Alzheimer's and

Gene cross-over in Neurodegenerative disease is loosely understood for diseases such as Parkinson’s, Alzheimer’s and Amytrophic Lateral Sclerosis (ALS). (Source: Cooper-Knock et al. Nature Reviews Neurology 2012 doi:10.1038/nrneurol.2012.156)

ADVERTISEMENT

Neurodegenerative disease (Parkinson’s, Huntington’s, ALS etc.) has experienced a massive boom in industry as of late, with a particular emphasis on Alzheimer’s, as we have been repeatedly stressing. Recent major developments include the development of a new phase III Tau-therapy for Alzheimer’s disease, as discovered by Wischik’s team at the University of Aberdeen (TauRX), and AsceNeuron’s new pre-clinical Tau-tangle inhibitor for Alzheimer’s and progressive supranuclear palsy (PSP).

Other potential research avenues for Alzheimer’s therapy are summarized in our review here.

Alan Thompson (Source: UCL)

Alan Thompson (Source: UCL)

This UCL collaboration will initially run for 3-years at Takeda Cambridge’s HQ, with the aim of developing mechanistic approaches to identifying gene targets for CNS therapies. It also looks to identify less-well understood cell signalling pathways in such neurodegenerative diseases. The gradual revival of hope for the biotech Alzheimer’s field has really taken of, and this is just another example of this new craze.

Alan Thompson, Dean of UCL’s Faculty in Brain Sciences, aptly put it:

Developing new treatments for devastating neurodegenerative diseases is an absolutely essential but very challenging goal and requires the complementary expertise of academia and industry, if it is to be achieved.”

Previous post

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Next post

Ablynx richly rewarded for MSD's Nanobody Proof in Immuno-Oncology

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.